Raymond Cheong
Directeur/Membre du Conseil chez TALIS BIOMEDICAL CORPORATION
Fortune : - $ au 30/04/2024
Postes actifs de Raymond Cheong
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| TALIS BIOMEDICAL CORPORATION | Directeur/Membre du Conseil | 10/03/2023 | - |
| MADRIGAL PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 15/06/2023 | - |
| VTV THERAPEUTICS INC. | Directeur/Membre du Conseil | 27/02/2024 | - |
Istari Oncology, Inc.
 Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Directeur/Membre du Conseil | 01/12/2018 | - |
Historique de carrière de Raymond Cheong
Anciens postes connus de Raymond Cheong
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| TALIS BIOMEDICAL CORPORATION | Directeur/Membre du Conseil | 01/06/2020 | 10/06/2022 |
Formation de Raymond Cheong
| University of Maryland | Undergraduate Degree |
| The Johns Hopkins University | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
Opérationnelle
| Director/Board Member | 5 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| TALIS BIOMEDICAL CORPORATION | Health Technology |
| MADRIGAL PHARMACEUTICALS, INC. | Health Technology |
| VTV THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Health Technology |
- Bourse
- Insiders
- Raymond Cheong
- Expérience
